VD
Verici Dx plc Stock: price and insider trades · United Kingdom
Verici Dx plc: what insiders have been doing
We have very little insider data for Verici Dx plc so far: the most recent filing dates from 7 December 2022. With so few records, no pattern can be drawn yet. Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 23,386 of 26,914 companies
24.9
score / 100
Value4
Quality46
FCF yld-62%
Earn yld-51%
EV/EBITDA·
ROE-192%
Gross mgn77%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
£0.00
Analyst consensus
1 analysts£0.03Target £0.03(+1315%)£0.03
Income statement
Revenue£3.7M
Gross profit£2.8M77% margin
EBITDA-£6.3M-173% margin
Net income-£6.9M-223.7% margin
Valuation
P/Book68.6x
Beta1.18
Balance sheet & cash
Market cap£13.7M
Total debt£197k
Free Cash Flow-£8.5M
Debt / Equity14%
Profitability & ownership
ROE-192.2%
ROA-77.6%
% insiders1.4%
% institutions45.8%
Last declaration on 7 December 2022
Declarations1 total
- 354,370 sharesOutside a trading venueISIN GB00BM8HZD43FCA-NSM:4603474
1 of 1 declaration
About Verici Dx plc
Verici Dx plc is a company focused on developing diagnostic tests to assess the health of organ transplants. It is listed on the London Stock Exchange.
